neuralink.com

Neuralink is a company developing an implanted brain-computer interface (BCI) that records neural activity and translates it into digital commands, with the stated goal of restoring autonomy to people with unmet medical needs. As of its current stage, this is research technology tested through clinical trials — not a commercially available treatment. If you or someone you care for has quadriplegia, paraplegia, or ALS and is wondering whether Neuralink is an option, the practical answer is: it may only be reachable through trial enrollment, and the first real step is talking to a clinician and checking official eligibility rather than acting on news coverage.

What Neuralink's BCI actually does

A brain-computer interface bypasses the body's normal output pathways. Instead of a muscle moving a cursor, neural signals are recorded directly and decoded into commands a computer can use.

Neuralink's approach centers on an implanted device that:

• Records neural signals from the brain.
• Transmits those signals to external hardware and software.
• Decodes the signals into digital actions — the company frames the goal as a "generalized brain interface," meaning one system intended to serve many kinds of output rather than a single fixed task.

The intended use cases described by the company focus on people who have lost function due to neurological injury or disease — for example, restoring communication and control for people with quadriplegia, paraplegia, or ALS. In plain terms, the aim is to let someone control a computer or similar device through thought rather than movement.

The PRIME Study: what a human trial involves

Neuralink's human trial is the PRIME Study. It is a research study, which shapes what participation realistically looks like.

What participation generally involves

• Surgical implantation of the device, since this is an implanted BCI rather than a wearable.
• Training and calibration so the system can learn to interpret that individual's neural signals.
• Ongoing sessions and follow-up to use the interface and collect study data.
• Commitment to the study protocol, including assessments — trial participation is a research relationship, not a one-time procedure.

Who may qualify

Eligibility is defined by the study, not by the company's public messaging. Trials of this kind typically focus on people with severe motor impairment, such as quadriplegia, and the specific inclusion and exclusion criteria are set by the researchers. Because criteria can change and are study-specific, the only reliable source is the official trial listing and the study team.

What it is not

The PRIME Study is not a commercially available treatment. You cannot currently schedule this as a standard clinical procedure. Participation means enrolling in research, with the uncertainties that come with it.

How this differs from existing assistive technology

It's easy to overestimate availability by comparing Neuralink to products people already use. These are different categories:

The practical takeaway: if you need assistive technology today, established options are the realistic starting point, while Neuralink remains a research pathway.

Practical next steps for patients and caregivers

1. Talk to a clinician — ideally a neurologist or rehabilitation specialist familiar with your condition — about what assistive options exist now and whether any trial might be appropriate.
2. Check official trial information rather than headlines. Look for the PRIME Study's official listing and eligibility criteria, and confirm details with the study team.
3. Ask specific questions before considering enrollment: What does the surgery and recovery involve? What is the time commitment? What follow-up is required? What is known and unknown about outcomes?
4. Separate research from treatment in your planning. Build your current care around available options, and treat trial participation as a distinct decision.

Neuralink is best understood as a company pushing an implanted BCI through human trials toward potential future use — promising in direction, but still research-stage. The responsible path for anyone with a qualifying condition is clinical guidance plus verification against official trial sources.

Neuralink's human trial is the PRIME Study (Precise Robotically Implanted Brain-Computer Interface), an early-stage feasibility trial testing the N1 implant and the R1 surgical robot in people with severe motor impairment. You do not apply directly to the trial; you join Neuralink's patient registry, and the team contacts registry members who may match the study's eligibility criteria. Because this is a first-in-human feasibility study, participation means surgery, regular follow-up visits, and a set of risks and unknowns that are still being characterized.

What the PRIME Study is testing

The study evaluates two pieces of hardware together:

• The N1 implant — a small device placed in the brain that records neural activity and transmits it wirelessly to an external app. The goal is to let a person control a computer cursor or keyboard through thought alone.
• The R1 robot — a surgical robot designed to place the N1's fine threads into the brain with precision that a human surgeon could not achieve by hand.

The purpose at this stage is feasibility: can the implant and robot be used safely, and does the system let participants control a computer? It is not a trial of a finished consumer product, and it is not designed to cure the underlying condition.

Who is eligible

The study targets people with severe motor impairment, specifically those with:

• Quadriplegia
• Paraplegia
• ALS (amyotrophic lateral sclerosis)
• Other conditions causing severe motor impairment

Eligibility is not automatic for anyone in these groups. Neuralink reviews registry entries against the study's criteria, which include factors like age, the nature and stability of the condition, and whether a candidate can safely undergo surgery and take part in follow-up. The company has not published a complete public checklist, so the practical answer is: register, and let the screening process determine whether you fit.

What participation involves

If you are selected, participation generally includes:

1. Screening and consent — medical evaluation and a full explanation of the study, including risks, before you agree to take part.
2. Surgery — implantation of the N1 using the R1 robot, performed by a surgical team.
3. Device training and use — learning to use the implant to control a computer, typically through the Neuralink app.
4. Follow-up visits — scheduled sessions to monitor the implant, your health, and how the system performs over time.

The exact schedule, number of visits, and duration are set by the study protocol and explained during screening.

How to apply

Neuralink does not accept direct trial applications. The path is:

1. Go to Neuralink's patient registry on the company's website.
2. Submit your information through the registry form.
3. Wait to be contacted — Neuralink reaches out to registry members who may be eligible for the PRIME Study or future trials.
4. If contacted, complete screening and, if you qualify and choose to proceed, enroll.

Registering does not guarantee selection, and being contacted does not guarantee enrollment.

Risks and unknowns

This is an early-stage feasibility trial, which shapes what participants should expect:

• Surgical risk — brain surgery carries risks including bleeding, infection, and complications from anesthesia or the procedure itself.
• Device risk — the implant may not work as intended, may stop functioning, or may need to be removed or replaced.
• Unknown long-term effects — because the technology is new in humans, long-term effects on brain tissue and device durability are not fully known.
• No guaranteed benefit — the study is testing whether the approach works, not delivering a proven treatment.

Anyone considering the registry should discuss it with their own physicians and weigh the trial's requirements against their situation. The decision is personal, and the study team is required to explain the risks in detail before anyone consents.

A brain-computer interface (BCI) is a system that reads neural signals, translates them into commands, and uses those commands to control an external device — such as a cursor, a robotic arm, or a speech synthesizer. BCIs are currently an active research and early clinical area, not a consumer product: today they are studied mainly with people who have severe paralysis or loss of communication, and access typically runs through clinical trials rather than retail purchase.

The basic signal chain

Every BCI, regardless of design, performs three jobs in sequence:

1. Recording — sensors capture electrical activity from the nervous system. This can be single neurons, small groups of neurons, or broad summed activity like EEG.
2. Decoding — software processes that signal (filtering out noise, extracting features) and maps patterns to an intended action. A person imagining "move right" produces a distinguishable pattern that the decoder learns to recognize.
3. Output — the decoded intent drives a device: a computer cursor, a keyboard, a prosthetic limb, or a speech device.

The loop is often closed: the user sees the result and adjusts, and the decoder is recalibrated over time. Performance depends heavily on signal quality, which is why the recording method matters so much.

Invasive vs. non-invasive approaches

The core tradeoff is signal quality versus surgical risk.

No approach dominates on every dimension. A research group prioritizing safety and broad access may choose non-invasive methods; one pursuing the highest possible control bandwidth may accept surgery. The right choice depends on the goal, the user's condition, and the risk the user and clinicians are willing to take.

What BCIs are actually used for now

Current work concentrates on restoring function lost to injury or disease, for example:

• Communication — letting a person with paralysis select letters or words to type, or synthesize speech, by controlling a cursor or directly decoding attempted speech.
• Movement and control — operating a robotic arm, a wheelchair, or a computer to regain some physical independence.
• Clinical research — studies with people who have quadriplegia, paraplegia, or ALS, where the aim is to restore autonomy that standard assistive technology cannot.

These are early-stage results from small numbers of participants. They demonstrate that the concept works in controlled settings; they do not yet mean BCIs are a routine, widely available treatment.

Why it isn't a consumer product yet

Several constraints keep BCIs in the lab and clinic:

• Durability — implanted electrodes can degrade or lose signal over months and years.
• Calibration — decoders often need retraining, and performance can drift between sessions.
• Surgery and safety — invasive systems carry real risks that must be justified by the benefit.
• Scale — most published results involve a handful of participants, so generalization is unproven.

If you are evaluating a specific BCI program, the useful questions are: What recording method does it use? What condition is it designed for? Is it offered through a clinical trial, and what are the eligibility criteria? Those answers, not the general concept, determine whether it applies to a given person.

A clinical trial is a research study in which people volunteer to test a medical intervention—a drug, device, procedure, or behavioral change—to answer questions about its safety and whether it works. You join one by finding a study that matches your condition, confirming you meet its eligibility criteria, and completing the study team's screening and informed consent process. Trials are not a guaranteed treatment: they are experiments, and participation always carries uncertainty. The sections below explain how trials are structured, how eligibility works, and what to ask before you enroll, using Neuralink's PRIME study of an implanted brain-computer interface as a concrete example.

What a clinical trial actually is

A clinical trial is a controlled experiment run under a written protocol—a document that specifies who can participate, what intervention they receive, how outcomes are measured, and how risks are monitored. Trials are typically sponsored by a company, university, hospital, or government agency and reviewed by an institutional review board (IRB) or ethics committee before any participant is enrolled.

The purpose is to generate evidence. A trial does not exist to deliver care to an individual; it exists to answer a question that can later inform care for many people. That distinction matters when you weigh whether to join.

The main phases

Early-stage device trials often blend features of Phase 1 and Phase 2: the primary goal is safety and feasibility, with preliminary signals about function. Neuralink's PRIME study is described as an early-stage trial of an implanted brain-computer interface aimed at people with quadriplegia, paraplegia, or ALS—conditions where the goal is restoring some degree of control or communication rather than curing the underlying condition.

Why eligibility criteria are so specific

Every trial defines who may participate. Criteria usually include:

• Condition and diagnosis — the specific disease, injury level, or functional status being studied.
• Age and general health — to reduce confounding factors and risk.
• Prior treatments — some trials exclude people who have already received a particular therapy.
• Practical factors — ability to travel to the study site, attend follow-up visits, and comply with the protocol.

This is why trials target narrow groups such as people with quadriplegia or ALS. A device implanted in the brain must be tested in people whose condition matches the intended use, and the study team needs to interpret results without too many unrelated variables. If you do not meet the criteria, it is not a judgment about your case—it means the study was not designed to answer a question about someone like you.

Informed consent: what you are actually agreeing to

Informed consent is a process, not a signature. Before enrolling, the study team must explain:

• The purpose of the trial and why you are being asked.
• What procedures you will undergo, including surgery, imaging, or device implantation if applicable.
• Known risks and the possibility of unknown risks.
• Potential benefits, and the explicit statement that benefit is not guaranteed.
• Alternatives to participating, including standard care.
• Your right to withdraw at any time without losing access to other care.
• How your data and biological samples will be used and shared.

You should be able to ask questions until you understand the tradeoffs, and you can take the consent form home before deciding. If anything is unclear, ask the study coordinator to walk through it again.

How to find trials and evaluate them

Start with registries and your own care team:

1. Search a public registry. ClinicalTrials.gov (and equivalent national registries) lets you filter by condition, intervention, phase, and location. Read the "Eligibility Criteria" and "Contacts and Locations" sections carefully.
2. Ask your specialist. Neurologists, physiatrists, and other specialists often know which trials are recruiting in your area or can refer you to a center.
3. Contact the study team directly. Use the listed contact to ask whether you might qualify before investing time in travel or records.
4. Read the protocol summary. Look for the primary outcome—what the study is actually measuring—and the follow-up schedule.

Questions to ask before enrolling

• What is the primary goal of this trial—safety, feasibility, or effectiveness?
• What procedures will I undergo, and how invasive are they?
• How many visits are required, and over how long?
• Who pays for the intervention, travel, and any complications?
• What happens if the device or treatment does not work, or if I want to stop?
• Will I be told results, and when?
• What are the alternatives if I do not join?

Write the answers down. If a team cannot answer a basic question about risks or costs, that is useful information.

Risks, benefits, and the decision to join

Participating in a trial can offer access to an intervention before it is widely available, closer monitoring, and the chance to contribute to research that may help others. It can also mean unknown side effects, procedures that carry their own risks (especially with implanted devices), time commitments, and the possibility that the intervention does not help you.

For an early-stage device trial like PRIME, the surgical implantation of a brain-computer interface and the long-term presence of hardware are central considerations. Discuss with your own physician how the trial's procedures compare with your current care, and whether the potential benefits justify the risks for your situation. No one should feel pressured to enroll, and declining a trial does not close the door to future options.

A practical checklist

• Confirm the trial is registered and recruiting.
• Verify you meet the eligibility criteria before contacting the team.
• Read the informed consent document in full and ask questions.
• Clarify costs, travel, and follow-up obligations in writing.
• Talk with your treating physician about how participation fits your care.
• Know your right to withdraw at any time.

A clinical trial is a structured experiment, and joining one is a decision you make with full information—not a default next step. Use the registry, your care team, and the study's own documents to decide whether a specific trial is right for you.

ALS (amyotrophic lateral sclerosis) is a progressive motor neuron disease that damages the nerve cells controlling voluntary muscles, leading to weakness, loss of movement, and eventually difficulty breathing. It is also known as Lou Gehrig's disease, after the baseball player diagnosed with it in 1939, and is classified as a form of motor neuron disease (MND). The ALS Therapy Development Institute (ALS TDI) describes itself as the largest drug discovery lab in the world focused solely on finding treatments for ALS — a useful starting point if you want to understand both the disease and where research currently stands.

What ALS Is and Who It Affects

ALS attacks motor neurons — the nerve cells in the brain and spinal cord that carry signals to muscles. As these neurons degenerate, muscles stop receiving signals and begin to weaken and waste away. The disease does not typically affect the senses (sight, hearing, touch, taste, smell) or, in most cases, bladder and bowel control, which distinguishes it from some other neurological conditions.

The terminology can be confusing, so it helps to separate the names:

ALS can affect adults of any age, though it most commonly appears in middle to later life. Because the disease varies in how it starts and progresses, no two people experience exactly the same path.

Early Signs and Symptoms

Symptoms usually begin subtly and may be noticed first in the hands, arms, legs, or muscles involved in speaking and swallowing. Common early signs include:

• Muscle weakness — trouble gripping objects, lifting, walking, or climbing stairs
• Muscle twitching (fasciculations) and cramping
• Muscle wasting (atrophy) in the hands, arms, or legs
• Slurred or thick speech (dysarthria)
• Difficulty swallowing (dysphagia)
• Tripping or dropping things due to weakness
• Emotional changes in some people, such as inappropriate laughing or crying (pseudobulbar affect)

Because these symptoms overlap with many other, more treatable conditions, they do not by themselves mean a person has ALS. That overlap is one reason diagnosis is not immediate.

How ALS Is Diagnosed

There is no single test that confirms ALS. Diagnosis is a clinical process: a neurologist evaluates symptoms, examines motor and sensory function, and rules out conditions that mimic ALS — such as certain nerve disorders, spinal cord problems, and other motor neuron diseases.

The process typically involves:

1. Medical history and neurological exam — assessing weakness, reflexes, muscle tone, and coordination
2. Electromyography (EMG) — measuring electrical activity in muscles to detect motor neuron damage
3. Nerve conduction studies — checking how well nerves carry signals
4. MRI and other imaging — looking for structural causes of symptoms
5. Blood and other lab tests — excluding treatable conditions with similar symptoms

Because ALS is diagnosed by exclusion, confirming it can take time. Symptoms may need to be observed and monitored before a neurologist is confident in the diagnosis. This delay is common and does not necessarily indicate uncertainty about the eventual conclusion.

Current Treatment Approaches

There is currently no cure for ALS, and treatment focuses on slowing progression where possible, managing symptoms, and maintaining quality of life. What treatment can and cannot do is important to understand:

• Can slow the rate of decline in some people, depending on the specific therapy and the individual
• Can relieve symptoms such as muscle cramps, spasticity, excess saliva, and breathing difficulty
• Can support nutrition, communication, and mobility through assistive devices and therapies
• Cannot reverse existing motor neuron damage or restore lost muscle function
• Cannot stop progression entirely in most cases

Care is typically delivered by a multidisciplinary team — neurologists, physical and occupational therapists, speech-language pathologists, respiratory specialists, dietitians, and social workers — because ALS affects many body systems over time. A neurologist is the right person to discuss which specific treatments are appropriate for an individual, as options and eligibility vary.

Where to Find Credible Research Updates and Support

Because ALS research moves quickly, reliable updates matter. The ALS Therapy Development Institute (als.net) is one source focused specifically on ALS drug discovery, and it offers a way to receive updates through its subscribe page. Other credible resources include academic medical centers with ALS clinics, national ALS associations, and patient registries that connect people to research studies.

When evaluating any ALS information, look for:

• Named medical or research institutions behind the content
• Clear distinction between approved treatments and experimental research
• Dates on research updates, since findings evolve
• Contact routes to ALS clinics or specialists for personal medical questions

For anyone newly researching ALS — whether for themselves or a family member — the practical next step is usually to consult a neurologist experienced with motor neuron disease, while using research organizations like ALS TDI to stay informed about the science as it develops.